{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=52",
    "query": {
      "condition": "Growth Disorders",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 1312,
    "total_pages": 132,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T09:30:44.420Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01367834",
      "title": "Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Turner Syndrome"
      ],
      "interventions": [
        {
          "name": "somatotropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Knickmeyer Santelli, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Months",
        "maximum_age": "13 Months",
        "sex": "FEMALE",
        "summary": "11 Months to 13 Months · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2010-05",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01367834"
    },
    {
      "nct_id": "NCT00917384",
      "title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Cancer",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2009-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 14,
      "location_summary": "Bakersfield, California • La Jolla, California • Redlands, California + 11 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00917384"
    },
    {
      "nct_id": "NCT01918306",
      "title": "GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative Breast Cancer",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Triple Negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "GDC -0941",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01918306"
    },
    {
      "nct_id": "NCT05681299",
      "title": "Effects of GH and Lirglutide on AgRP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy",
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "growth hormone and lirglutide",
          "type": "DRUG"
        },
        {
          "name": "growth hormone",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-05-01",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05681299"
    },
    {
      "nct_id": "NCT05470504",
      "title": "Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin Receptor Mutation",
        "Partial Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Pegvisomant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2023-01-23",
      "completion_date": "2028-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470504"
    },
    {
      "nct_id": "NCT06827236",
      "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Unresectable Breast Carcinoma",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BNT323",
          "type": "DRUG"
        },
        {
          "name": "BNT327",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2025-04-23",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 28,
      "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06827236"
    },
    {
      "nct_id": "NCT02784509",
      "title": "Translational Investigation of Growth and Everyday Routines in Kids",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Childhood Obesity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "10 Years to 16 Years"
      },
      "enrollment_count": 342,
      "start_date": "2016-06",
      "completion_date": "2020-09",
      "has_results": true,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784509"
    },
    {
      "nct_id": "NCT00807365",
      "title": "Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Elderly"
      ],
      "interventions": [
        {
          "name": "GHRH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-12-17",
      "completion_date": "2010-04-29",
      "has_results": true,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807365"
    },
    {
      "nct_id": "NCT01204957",
      "title": "Brown Seaweed as a Breast Cancer Preventive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Seaweed and Soy Protein",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo and Soy Protein",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "1998-10",
      "completion_date": "1999-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204957"
    },
    {
      "nct_id": "NCT00634088",
      "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone + Lapatinib + Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2008-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-10",
      "last_synced_at": "2026-10-29T09:30:44.420Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634088"
    }
  ]
}